Biglycan

Mechanism of Action

• Acts as an endogenous TLR4 ligand (alarmin): released from damaged ECM, biglycan activates TLR4/MyD88/NF-kB in macrophages, driving IL-1beta and TNF-alpha production
• Promotes muscle hypertrophy: recombinant biglycan upregulates utrophin-A at the neuromuscular junction via PI3K/Akt, stabilizing the dystrophin-glycoprotein complex
• Regulates BMP-4 and BMP-2 bioavailability by sequestering them in ECM; biglycan-BMP complexes control bone morphogenesis
• Activates Wnt signaling in osteoblasts by interfering with sclerostin-LRP6 interaction, promoting bone formation
• Complement activation: biglycan binds complement component C1q and triggers classical pathway activation in damaged tissue

Research Findings

• Biglycan knockout mice develop progressive osteoporosis and myopathy; spontaneous aortic dissection in some backgrounds
• Recombinant human biglycan (rhBGN) administered weekly to mdx mice (Duchenne muscular dystrophy model) restored utrophin levels and improved muscle function
• Biglycan infusion in mdx mice protected against exercised-induced muscle damage for up to 3 weeks after a single injection
• Biglycan is a damage-associated molecular pattern (DAMP); elevated serum biglycan in sepsis and autoimmune disease correlates with disease severity
• BGN gene mutations linked to Meester-Loeys syndrome (X-linked connective tissue disorder resembling Marfan/Ehlers-Danlos overlap)

Research Protocols

• Duchenne muscular dystrophy research: 100 mg/kg IV weekly in mdx mice for muscle function assessment over 4-8 weeks
• Bone studies: 1-10 mg/kg SC or IV in ovariectomized rats; measure BMD and osteocalcin
• TLR4 signaling assay: 1-100 nM recombinant biglycan core protein on macrophages; measure IL-6/TNF-alpha
• In vitro myotube assay: 100-500 ng/mL rhBGN during C2C12 differentiation; quantify utrophin mRNA and protein

Interactions

• Decorin: structural paralog; biglycan activates TLR4 while decorin inhibits TLR4 via EGFR; opposing inflammatory roles
• BMP-2 and BMP-4: biglycan sequesters these BMPs; biglycan loss allows BMP over-signaling in some tissues
• Anti-TLR4 antibodies: block biglycan-mediated macrophage activation; therapeutic approach in sepsis

Safety Profile

Recombinant biglycan well tolerated in mdx mice at therapeutic doses. TLR4 agonism at high concentrations creates theoretical pro-inflammatory risk; therapeutic window appears favorable in DMD models. No approved clinical use; in preclinical stage for Duchenne muscular dystrophy.

Legal & Regulatory

Investigational; preclinical stage for DMD and bone disorders